Clinical Trials
18 trialsNCT05603910 2026-02-24
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
University of Miami
Phase 1 Recruiting
NCT05155189 2026-01-21
A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
Zhejiang University
Phase 1 Recruiting
NCT05273554 2026-01-12
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04427293 2025-12-16
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
University of Illinois at Chicago
Phase 1 Recruiting
NCT03524326 2025-05-13
Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03324373 2025-04-24
Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
University of Iowa
Phase 1 Completed
NCT05303090 2025-02-27
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer
Fudan University
Phase 1 Completed
NCT05803928 2024-07-24
Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies
Third Affiliated Hospital, Sun Yat-Sen University
Phase 1 Recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT05533892 2023-12-19
CCGLC-007
Tongji Hospital
Phase 1 Unknown
NCT05767684 2023-08-25
Neoantigen Derived DCs as Cancer Treatment
National Health Research Institutes, Taiwan
Phase 1 Unknown
NCT05675462 2023-03-06
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma
Fudan University
Phase 1 Unknown
NCT05225116 2023-02-08
Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Beijing Tsinghua Chang Gung Hospital
Phase 1 Unknown
NCT02788708 2022-09-19
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02935309 2022-05-31
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT05221775 2022-02-03
Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Unknown
NCT05171530 2021-12-29
Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer
Ruijin Hospital
Phase 1 Unknown
NCT02915172 2017-06-26
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Withdrawn